Cancer Meds Help Roche Beat 1Q Sales
Roche Holding AG reported a 5 percent increase in first-quarter sales as demand for three breast-cancer medicines from Europe’s largest drugmaker climbed. Sales grew to 12.4 billion Swiss francs ($12.9 billion), the Basel, Switzerland-based company said in a statement on Tuesday. That compared with the 12.3 billion-franc average of eight analyst estimates compiled by Bloomberg. Roche is counting on Esbriet, a new lung medicine whose sales almost doubled, and an experimental drug for multiple sclerosis that won expedited U.S. approval last quarter, to drive revenue growth in years ahead as products such as Lucentis age. Bloomberg’s Sam Fazali delves into the company’s news with Hans Nichols in Berlin and “On the Move” host Anna Edwards in London. Roche Holding Chief Executive Officer Severin Schwan joined them all for more.